Von Willebrand Disease — Research Summary
Printed from RareWays (rareways.com.au) on 5 April 2026
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Biology of von Willebrand disease.
Flood Veronica H et al. — Blood advances (14 April 2026)
https://pubmed.ncbi.nlm.nih.gov/41610306/
- 2.
Real-word evidence on healthcare resource use and associated costs in on-demand users of replacement therapies in von Willebrand disease in France: the FORvWARD study.
Polack Benoit et al. — Journal of comparative effectiveness research (1 April 2026)
https://pubmed.ncbi.nlm.nih.gov/41870437/
- 3.
Higher-dosed clotting factor prophylaxis fails to reduce postpartum hemorrhage in women with von Willebrand disease: findings from the observational PRegnancy and Inherited bleeding DisordErS study.
de Vaan Anne et al. — Journal of thrombosis and haemostasis : JTH (1 April 2026)
https://pubmed.ncbi.nlm.nih.gov/41512963/
- 4.
Anovulatory bleeding and the spectrum of bleeding disorders: Understanding heavy menstrual bleeding in adolescents.
Özer Emre et al. — International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics (1 April 2026)
https://pubmed.ncbi.nlm.nih.gov/41074491/
- 5.
Past, Present, and Future of von Willebrand Disease.
McGrath Mary et al. — Advances in therapy (28 March 2026)
https://pubmed.ncbi.nlm.nih.gov/41902888/
Clinical Trials — Currently Recruiting (Australia)
Ask your doctor whether you or your child may be eligible for any of these trials.
- 1.
Study of BB-025, Alone and After BB-031, in Healthy Volunteers
Recruiting — Phase 1 — Basking Biosciences, Inc.
https://clinicaltrials.gov/study/NCT07202663
- 2.
A Study of Bleeding and Treatment in Participants With Von Willebrand Disease
Recruiting — Hemab ApS
https://clinicaltrials.gov/study/NCT06610201
- 3.
A Study Assessing HMB-002 in Participants With Von Willebrand Disease
Recruiting — Phase 1 — Hemab ApS
https://clinicaltrials.gov/study/NCT06754852
- 4.
Study of VGA039 in Healthy Volunteers and Patients With Von Willebrand Disease (VIVID)
Recruiting — Phase 1 — Vega Therapeutics, Inc
https://clinicaltrials.gov/study/NCT05776069
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Von Willebrand Disease
Von Willebrand Disease is the most common inherited bleeding disorder, caused by a deficiency or dysfunction of von Willebrand factor — a protein essential for blood clotting. It affects approximately 1% of the global population, though most cases are mild. Symptoms include easy bruising, prolonged bleeding from cuts, and heavy menstrual periods.
Most Recent Research
Von Willebrand factor (VWF) is a key coagulation protein, tethering platelets to the sites of injury through binding sites for platelet glycoprotein Ibα and exposed subendothelial collagen. VWF synthesis occurs in endothelial cells and megakaryocytes, a complex process involving the VWF propeptide, dimerization and multimerization, and glycosylation. Von Willebrand disease results from defects or dysfunction in VWF and includes both quantitative and qualitative issues with the VWF protein. VWF is cleaved by ADAMTS13 and ultimately cleared from circulation. Although it is clear that VWF plays an important role in clot formation, it may also be important in a number of other areas including angiogenesis. Our knowledge of VWF has come a long way in the 100 years since the first publication by Erik von Willebrand in 1926 thanks to a large number of researchers in the VWF biology field.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.